GlaxoSmithKline beat expectations in the first-quarter results when it stood by its forecasts for this year and its turnover rose to about $12 billion, boosted by $1.6 billion in sales of its COVID-19 antibody treatment Xevudy https://t.co/JOm7r1z8OW pic.twitter.com/neNz9sqsRk— Reuters (@Reuters) April 27, 2022
(SocialLY brings you all the latest breaking news, fact checks and information from social media world, including Twitter (X), Instagram and Youtube. The above post contains publicly available embedded media, directly from the user's social media account and the views appearing in the social media post do not reflect the opinions of LatestLY.)













Quickly


